idogen

Idogen

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Last week I announced, I would take a closer look at some companies a reader, Kenneth, had invested in. In this post I’ll take a closer look at Idogen, listed on Aktietorget. The Idogen share has more than doubled the past three months (+ 61% in 2016) and had significant momentum between Mid-June and the first week of August. The momentum seems to have vanished, though. The past month the share has hovered around 12 SEK. My conclusion is that Idogen is a high risk investment and that the present price is a better exit-price than entry-price. Continue reading

BrainCool2016

Trigger at work – Recyctec and BrainCool up

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The thing for the investor about growth shares or start-ups are news to trigger higher share prices. Milestones or accomplishments triggering a steep rise in share price is what we long for. The main activity in 2016, though, from many companies seems to have been raising money through issues. And this does not trigger higher share prices – on the contrary! Press releases announcing news, causing the share to rise have been too sparse so far. This week was different. There was good news from both BrainCool and Recyctec. Continue reading

dissapointing turnover i August

I looked for turnover – and found probable issues

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The past week Dignitana, BrainCool, Heliospectra and CybAero have issued their half year reports. All four companies have products, on-going sales and are aiming to penetrate their markets. BrainCool have made their first turnover in Q2. For an investor the development of sales, both in terms of turnover and growth are the focal point. To make it short: I’m a bit disappointed.

Furthermore, in 2016 8 out of 11 companies in my portfolio have made issues, and after the reports we will probably see 2 more in the next couple of months. Continue reading

August reports

Reports in August

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

August is the season for H1-reports. For most companies in my portfolio the reports are no-news-events. The most interesting events are mainly non-financial. Companies always communicate these in press releases whenever they occur.

Often the impact of reports on share prices are marginal. Personally, my focus is on how the company describes its development. Consequently, I spend little time on numbers and most on words. Of course, turnover moves into focus as the company progresses and their market penetration starts. Later on, margins and profits moves into focus. Continue reading

Recyctec report

The report season is on

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

And the first to arrive was the half year report from Recyctec. Indications of a terrible report came as a ‘status update’ came out the day before the actual report. The bad news was hidden behind some good. The main point was a postponement of breakeven to fourth quarter 2016. Cause? A piece of equipment with copper, causing a miscolouring of the products. The pieces is replaced, but before the end of August, the production will still be low.

The effect of the production problems was almost no turnover in Q2 – symbolic 1,650 SEK. The no-turnover in Q2 and half of Q3 puts heavy pressure on cash and to compensate that the company announced an private placement of 10 MSEK – the third private placement this year.

To make it short: The share dropped from 8.05 on Wednesday to 6.40 on Friday – down 20.5 %. Continue reading

Portfolio performance H1-16

Portfolio performance – first half 2016

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

Well, the portfolio performance the past six months have been depressing and the overall performance is rather poor. On the other hand, it seems that at least for a few of the companies early summer has been a turning point.

In overall, the average share price in the portfolio is down 23 % during the first six months of 2016. In Q2, the average is minus 14.7 %. In comparison, the SPI-index (all Nasdaq-shares in Sweden) is down 4.3 % in 2016 and down 1.3 % in Q2. Compared to the performance of the portfolio in 2015, where the full-year result was +78.6%, 2016 seem dull and depressing. Check the December update for details. Continue reading

Homo Nervousus

Homo Nervousus – a sub-species of Homo Sapiens?

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

It is an (almost) known fact that investors are nervous people of the species Homo Nervousus. This specises hates uncertainty most of all. When uncertainty is up, they flee and shares are down. Since we cannot predict the result of the British referendum next week, as we could not last summer predict the actions of the Greek minister of finance or the outcome of their sudden referendum in July, it influences the markets. Uncertainty is up and shares are down. Continue reading

Recyctec report

Recyctec almost there

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The past months, Recyctec have delivered a steady stream of news, some financial some on business development. On several occasions, I have mentioned Recyctec, and I thought it to be the right time, here halfway through 2016, to sum up the development of the company. It is no secret that I see the present share price far from a fair valuation of the company. On the other hand, it is true that the delays during last autumn did put strings on the company. Continue reading

Almost successful issues

Almost successful issues

Facebooktwittergoogle_pluslinkedinmailFacebooktwittergoogle_pluslinkedinmail

The past two post I have focused on issues and IPO. This again will be the topic but from a different angel since A1M Pharma completed their issue this week and BrainCool announced a very peculiar form of private placement. Some issues are at best almost successful issues, which A1M Pharma is an example of. And of course there is the farce of the week: the postponed listing of lauritz.com. That wasn’t even ‘almost successful’ but straight out unsuccessful and made the laugh of the month. Continue reading